Zoetis Inc. (NYSE:ZTS) Shares Sold by Livforsakringsbolaget Skandia Omsesidigt

Livforsakringsbolaget Skandia Omsesidigt cut its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 13.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,530 shares of the company’s stock after selling 400 shares during the period. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Zoetis were worth $412,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. AMF Tjanstepension AB boosted its holdings in Zoetis by 23.4% in the third quarter. AMF Tjanstepension AB now owns 105,376 shares of the company’s stock worth $20,594,000 after acquiring an additional 20,001 shares in the last quarter. CWM LLC boosted its stake in Zoetis by 1.8% in the 3rd quarter. CWM LLC now owns 19,330 shares of the company’s stock worth $3,777,000 after purchasing an additional 339 shares in the last quarter. Wedmont Private Capital grew its position in Zoetis by 15.1% during the 3rd quarter. Wedmont Private Capital now owns 2,958 shares of the company’s stock worth $554,000 after purchasing an additional 388 shares during the last quarter. Quotient Wealth Partners LLC increased its stake in Zoetis by 15.6% during the 3rd quarter. Quotient Wealth Partners LLC now owns 3,562 shares of the company’s stock valued at $696,000 after purchasing an additional 480 shares in the last quarter. Finally, Pinnacle Bancorp Inc. increased its stake in Zoetis by 8.6% during the 3rd quarter. Pinnacle Bancorp Inc. now owns 3,595 shares of the company’s stock valued at $702,000 after purchasing an additional 285 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

NYSE:ZTS opened at $171.37 on Friday. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. The company has a 50 day moving average price of $169.34 and a 200-day moving average price of $179.28. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $200.53. The firm has a market cap of $77.32 billion, a price-to-earnings ratio of 32.21, a price-to-earnings-growth ratio of 2.77 and a beta of 0.90.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be given a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.17%. Zoetis’s dividend payout ratio (DPR) is currently 37.59%.

Analyst Ratings Changes

ZTS has been the topic of a number of research analyst reports. Leerink Partners initiated coverage on shares of Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price objective on the stock. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. UBS Group initiated coverage on Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective for the company. JPMorgan Chase & Co. upped their target price on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Finally, Morgan Stanley reduced their price target on shares of Zoetis from $248.00 to $243.00 and set an “overweight” rating for the company in a research report on Wednesday, January 29th. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $215.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.